Archive for May 2018

“We appreciate the attention that ICER’s review has brought to a disease that is often overlooked and undertreated. These new CGRP inhibitors are the first medicines developed and approved for the prevention of migraine attacks. With ICER finding that these medicines are cost-effective for migraine patients that have been failed by other treatments, we call…

“For the tens of millions of Americans who endure the pain and disabling effects of migraine disease, we congratulate Amgen and Novartis on the FDA approval of erenumab. This new class of medicine is the first to be developed and approved for the prevention of migraine attacks. We now call on all stakeholders in healthcare…